Psychiatric-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: A phase 3, randomized, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimized study in Europe
2012 ◽
Vol 60
(5)
◽
pp. S263
2013 ◽
Vol 23
(10)
◽
pp. 1208-1218
◽
2015 ◽
Vol 25
(2)
◽
pp. 141-149
◽
2007 ◽
Vol 29
(3)
◽
pp. 450-463
◽
2014 ◽
Vol 41
(2)
◽
pp. 34-39
◽
2002 ◽
Vol 59
(7)
◽
pp. 649
◽